Chemotherapy-Induced Neutropenia Treatment Market Report 2026

The chemotherapy-induced neutropenia treatment market size has grown strongly in recent years. It will grow from $0.62 billion in 2025 to $0.65 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of chemotherapy-induced neutropenia, expansion of aggressive cancer treatment protocols, availability of colony-stimulating factors, improved clinical monitoring practices, growth of oncology treatment facilities.

The chemotherapy-induced neutropenia treatment market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing adoption of long-acting growth factors, rising focus on outpatient neutropenia management, expansion of biosimilar g-csf usage, growing investment in infection prevention strategies, advancements in immunomodulatory therapies. Major trends in the forecast period include increasing adoption of prophylactic g-csf therapy, rising use of early intervention treatment models, growing emphasis on infection risk reduction, expansion of personalized neutropenia management, enhanced monitoring of white blood cell levels.

The increasing occurrence of cancer is expected to fuel the growth of the chemotherapy-induced neutropenia treatment market over the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells throughout the body. The rising number of cancer cases is primarily linked to an aging population, as older individuals are more susceptible to cancer due to the accumulation of genetic mutations and a gradual weakening of immune function over time. Chemotherapy-induced neutropenia treatments support cancer care by reducing the risk of infections through immune system support, allowing patients to continue chemotherapy with fewer delays or interruptions. This leads to improved treatment outcomes by minimizing complications and enhancing overall patient safety and quality of life. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, representing more than 450 new cases per day, with males accounting for around 55% of diagnoses. Therefore, the rising incidence of cancer is driving the growth of the chemotherapy-induced neutropenia treatment market.

Major companies operating in the chemotherapy-induced neutropenia treatment market are focusing on the development of innovative products and obtaining regulatory approvals, such as long-acting formulations, to enhance patient convenience, reduce dosing frequency, and improve treatment adherence. Long-acting formulations are drug preparations designed to release active ingredients slowly over an extended period, thereby decreasing the need for frequent administration. For instance, in December 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Udenyca Onbody, a novel, ready-to-use on-body injector. This device automatically delivers a long-acting formulation of pegfilgrastim approximately 27 hours after chemotherapy, eliminating the need for a next-day injection. Udenyca Onbody enhances the patient experience by ensuring timely preventive treatment for chemotherapy-induced neutropenia while reducing clinic visits and supporting improved adherence.

In September 2025, Hanmi Pharmaceutical, a South Korea-based biopharmaceutical company, entered into a strategic partnership with Tabuk Pharmaceuticals to expand the regional availability of its biologic therapy, Rolontis (eflapegrastim), across the Middle East and North Africa (MENA) region. This partnership is designed to accelerate patient access to advanced neutropenia treatments, strengthen commercial capabilities in key international markets, and support Hanmi’s broader global expansion strategy. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company specializing in the development, manufacturing, and distribution of branded and generic medicines across the MENA region.

Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation.

North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy-induced neutropenia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chemotherapy-induced neutropenia treatment market by increasing costs of imported biologics, injectable devices, cold-chain storage equipment, and pharmaceutical raw materials. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported G-CSF products, while Asia-Pacific faces higher production and export-related expenses. These tariffs are contributing to higher treatment costs and budget constraints for oncology care providers. However, they are also promoting domestic biologics manufacturing, regional biosimilar development, and localized supply chain strengthening that improves long-term treatment availability.

The chemotherapy-induced neutropenia treatment market research report is one of a series of new reports that provides chemotherapy-induced neutropenia treatment market statistics, including chemotherapy-induced neutropenia treatment industry global market size, regional shares, competitors with a chemotherapy-induced neutropenia treatment market share, detailed chemotherapy-induced neutropenia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy-induced neutropenia treatment industry. This chemotherapy-induced neutropenia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy-induced neutropenia treatment refers to the medical management strategies used to support cancer patients who experience reduced white blood cell counts following chemotherapy. These treatments help shorten the duration and lessen the severity of neutropenia, thereby reducing the risk of infections. Management typically includes the use of growth factors and adjustments to chemotherapy dosing, with early intervention helping patients maintain treatment schedules and improve overall outcomes.

The main types of chemotherapy-induced neutropenia treatment include antibiotic therapy, granulocyte colony-stimulating factor (G-CSF) therapy, granulocyte transfusion, and other approaches. Antibiotic therapy involves the use of antibiotics to prevent or treat bacterial infections by inhibiting bacterial growth or destroying bacteria. The routes of administration include subcutaneous and intravenous methods. Key indications include solid tumors, hematological malignancies, and other related conditions. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are primarily used by hospitals, specialty clinics, and homecare settings.

The chemotherapy-induced neutropenia treatment market consists of revenues earned by entities by providing services such as neutrophil count monitoring, chemotherapy dose management, patient education and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemotherapy-induced neutropenia treatment market also includes sales of biologics, biosimilars, and supportive care devices such as auto-injectors and on-body delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.